RT Journal Article
SR Electronic
T1 Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.20.22269599
DO 10.1101/2022.01.20.22269599
A1 Staessen, Jan A.
A1 Wendt, Ralph
A1 Yu, Yu-Ling
A1 Kalbitz, Sven
A1 Thijs, Lutgarde
A1 Siwy, Justyna
A1 Raad, Julia
A1 Metzger, Jochen
A1 Neuhaus, Barbara
A1 Papkalla, Armin
A1 von der Leyen, Heiko
A1 Mebazaa, Alexandre
A1 Dudoignon, Emmanuel
A1 Spasovski, Goce
A1 Milenkova, Mimoza
A1 Canevska-Taneska, Aleksandra
A1 Psichogiou, Mina
A1 Rajzer, Marek W.
A1 Fulawka, Lukasz
A1 Dzitkowska-Zabielska, Magdalena
A1 Weiss, Guenter
A1 Feldt, Torsten
A1 Stegemann, Miriam
A1 Normark, Johan
A1 Zoufaly, Alexander
A1 Schmiedel, Stefan
A1 Seilmaier, Michael
A1 Rumpf, Benedikt
A1 Banasik, Mirosław
A1 Krajewska, Magdalena
A1 Catanese, Lorenzo
A1 Rupprecht, Harald
A1 Czerwienska, Beata
A1 Peters, Björn
A1 Nilsson, Åsa
A1 Rothfuss, Katja
A1 Lübbert, Christoph
A1 Mischak, Harald
A1 Beige, Joachim
A1 the CRIT-Cov-U investigators
YR 2022
UL http://medrxiv.org/content/early/2022/01/23/2022.01.20.22269599.abstract
AB Background The SARS-CoV-2 pandemic remains a worldwide challenge. The CRIT-Cov-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression. Following the interim analysis demanded by the German government, the full dataset was analysed to consolidate findings and propose clinical applications.Methods In eight European countries, 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression, receiver operating curve analysis with comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalistion costs standardised across countries.Findings The entry WHO scores were 1-3, 4-5 and 6 in 445 (44·0%), 529 (52·3%), and 38 (3·8%) patients, of whom 119 died and 271 progressed. The standardised odds ratios associated with COV50 for death were 2·44 (95% CI, 2·05-2·92) unadjusted and 1·67 (1·34-2·07) if adjusted for sex, age, body mass index, comorbidities and baseline WHO score, and 1·79 (1·60-2·01) and 1·63 (1·40-1·90), respectively, for disease progression (p<0·0001 for all). The predictive accuracy of optimised COV50 thresholds were 74·4% (95% CI, 71·6-77·1) for mortality (threshold 0·47) and 67·4% (64·1-70·3) for disease progression (threshold 0·04). On top of covariables and the baseline WHO score, these thresholds improved AUCs from 0·835 to 0·853 (p=0·0331) and from 0·697 to 0·730 (p=0·0008) for death and progression, respectively. Of 196 ambulatory patients, 194 (99·0%) did not reach the 0·04 threshold. Earlier intervention guided by high-risk COV50 levels should reduce hospital days with cost reductions expressed per 1000 patient-days ranging from M€ 1·208 (95% percentile interval, 1·035-1·406) at low risk (COV50 <0·04) to M€ 4·503 (4·107-4·864) at high risk (COV50 ≥0·04 and age ≥65 years).Interpretation The urinary proteomic COV50 marker is accurate in predicting adverse COVID-19 outcomes. Even in mild-to-moderate PCR-confirmed infections (WHO scores 1-5), the 0·04 threshold justifies earlier drug treatment, thereby reducing hospitalisation days and costs.Funding German Federal Ministry of Health acting upon a decree from the German Federal Parliament.Competing Interest StatementHM is the co-founder and co-owner of Mosaiques-Diagnostics GmbH, JS and JR are employees of Mosaiques-Diagnostics GmbH, Hannover, Germany.Funding StatementThe study was funded by the German Federal Ministry of Health acting upon a decree from the German Federal Parliament.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the German-Saxonian Board of Physicians, Dresden, Germany (number, EK BR 88/20.1) and the Institutional Review Boards of the recruiting sites provided ethical clearance.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study protocol is available at the German Register for Clinical Studies (www.drks.de), number DRKS00022495. Anonymised participants data will be made available upon request directed to the corresponding author. Proposals will be reviewed and approved by the funder, investigators and collaborators based on scientific merit. After approval of a proposal, data can be shared through a secure online platform after signing a data access and confidentiality agreement. Data will be made available for a minimum of 3 years after a request has been received and approved.